Search | Clinical Trials Finder

Conditions: High Risk Cancer, Lung Cancer
Interventions: Median LCS; Device
Lead sponsor: Median Technologies; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Memphis, Tennessee • Houston, Texas

Conditions: CNS Germ Cell Tumor
Interventions: Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 5
States / cities: Phoenix, Arizona • Los Angeles, California • New York, New York + 1 more

Conditions: Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
Interventions: lovastatin, placebo, biopsy, laboratory biomarker analysis; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Orange, California • Tampa, Florida • Salt Lake City, Utah

Conditions: Complication of Transplant
Interventions: Prograf, Tacrolimus, Sandoz, Tacrolimus, Reddy Laboratory, Tacrolimus, Mylan, Tacrolimus, Accord, Tacrolimus, Pancea Biotech Limited; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome
Interventions: RVU120(SEL120); Drug
Lead sponsor: Ryvu Therapeutics SA; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Miami, Florida • Atlanta, Georgia • St Louis, Missouri + 2 more

Conditions: Breast Cancer, Hot Flashes
Interventions: informational intervention; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bloodloss, Surgical Procedures, Operative
Interventions: Ecallantide, Cyklokapron(R); Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Aids-related Malignancies, Lymphoma, Precancerous Condition, Sarcoma
Interventions: polymerase chain reaction, cytology specimen collection procedure, histological technique, colposcopic biopsy; Genetic · Other · Procedure
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: BP1001 (varying dose), BP1001 (fixed dose), Dasatinib; Drug
Lead sponsor: Bio-Path Holdings, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gingivitis, Plaque
Interventions: sodium monofluorophosphate toothpaste; Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Covid19, SARS-CoV Infection
Interventions: Sargramostim, Placebo; Drug
Lead sponsor: Partner Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more

Conditions: Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
Interventions: coenzyme Q10, Placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 19
States / cities: Little Rock, Arkansas • San Francisco, California • Denver, Colorado + 14 more

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Loncastuximab, Roflumilast, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Barrett's Esophagus
Interventions: Proflavine, high resolution imaging; Drug
Lead sponsor: Anandasabapathy, Sharmila, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Retinitis Pigmentosa, X-linked Genetic Diseases
Interventions: docosahexaenoic acid OR corn/soy oil placebo; Drug
Lead sponsor: Retina Foundation of the Southwest; Other
Eligibility: 7 Years to 32 Years · Male only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Insulin Resistance
Interventions: Novel dietary fiber, Placebo; Other
Lead sponsor: Cargill; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Malignant Glioma
Interventions: Radiation Therapy, Radiosurgery, Stereotactic Biopsy, Temozolomide, Tumor Treating Fields Therapy, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy, Therapeutic Conventional Surgery; Radiation · Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Phoenix, Arizona • Jacksonville, Florida

Conditions: Fatigue
Interventions: Clinic-based physical therapy program., Home exercise program.; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Overactive Bladder
Interventions: Non-invasive neurostimulation device; Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Royal Oak, Michigan • Lawrenceville, New Jersey + 6 more

Conditions: Bleeding, Hemostatic Disorder
Interventions: POC Quantra QPlus System, Routine care; Device · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Capsule with folate, Vitamin B12 & pyridoxine, placebo; Dietary Supplement · Other
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Clinical High Risk, Psychosis, Remission, Conversion
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 12 Years to 30 Years
Enrollment: 2,617 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Irvine, California • Los Angeles, California • San Diego, California + 13 more

Conditions: Bladder Cancer
Interventions: Specimen Ultra-High field MRI, chemotherapy, Cystectomy and Lymphadenectomy; Procedure · Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prodromal Schizophrenia
Interventions: Step-Based Care Model; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 12 Years to 25 Years
Enrollment: 100 participants
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaMD

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

Lovastatin in Treating Patients At High Risk of Melanoma

Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial

Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery

Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Clinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in a Population With High Plaque/Low Gingivitis and High Plaque/High Gingivitis

Sargramostim Use in COVID-19 to Recover Patient Health

Clinical Trial of High Dose CoQ10 in ALS

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma

DHA and X-Linked Retinitis Pigmentosa

Effects of Novel Fiber on Glucose Homeostasis in Individuals at Risk for Diabetes

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

The Effects of Adding a Home Exercise Program to a Clinical Physical Therapy Program on Cancer-Related Fatigue

Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)

Quantra Point-of-Care Hemostasis Monitoring

Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia

AMP SCZ® Observational Study: PREDICT-DPACC

3 Tesla MRI in Patients With Bladder Cancer

Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis